An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Status: APPROVED_FOR_MARKETING
Study type: EXPANDED_ACCESS
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Eribulin Mesylate
Sponsor: Eisai Inc.